Jazz Pharmaceuticals - JAZZ Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $201.69
  • Forecasted Upside: 51.32 %
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$133.29
▲ +0.87 (0.66%)

This chart shows the closing price for JAZZ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Jazz Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JAZZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JAZZ

Analyst Price Target is $201.69
▲ +51.32% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $201.69, with a high forecast of $225.00 and a low forecast of $170.00. The average price target represents a 51.32% upside from the last price of $133.29.

This chart shows the closing price for JAZZ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 11 contributing investment analysts is to buy stock in Jazz Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 15 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/4/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/2/2022

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/29/2022The Goldman Sachs GroupBoost TargetNeutral$148.00 ➝ $170.00Low
9/21/2022The Goldman Sachs GroupLower TargetNeutral$192.00 ➝ $148.00Low
8/5/2022HC WainwrightLower Target$210.00 ➝ $204.00Low
8/4/2022BMO Capital MarketsBoost TargetOutperform$185.00 ➝ $188.00Low
8/4/2022SVB LeerinkBoost TargetOutperform$200.00 ➝ $210.00Low
8/4/2022UBS GroupLower TargetBuy$194.00 ➝ $191.00Low
8/4/2022Morgan StanleyBoost TargetEqual Weight$174.00 ➝ $187.00N/A
6/13/2022UBS GroupInitiated CoverageBuy$194.00Medium
5/5/2022CowenBoost Target$200.00 ➝ $225.00Low
5/5/2022CowenBoost Target$200.00 ➝ $225.00Low
5/5/2022Piper SandlerLower Target$197.00 ➝ $193.00Low
4/6/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$202.00 ➝ $196.00High
3/3/2022HC WainwrightBoost TargetBuy$210.00 ➝ $215.00Low
3/2/2022Cantor FitzgeraldReiterated RatingOverweightLow
3/2/2022Piper SandlerLower TargetOverweight$209.00 ➝ $197.00High
3/2/2022Royal Bank of CanadaLower TargetOutperform$216.00 ➝ $214.00High
3/2/2022BMO Capital MarketsLower Target$202.00 ➝ $187.00High
2/7/2022Needham & Company LLCReiterated RatingBuy$215.00Low
1/20/2022Truist FinancialBoost Target$180.00 ➝ $200.00Low
12/20/2021SVB LeerinkLower TargetOutperform$230.00 ➝ $200.00Low
12/17/2021Needham & Company LLCLower TargetBuy$220.00 ➝ $215.00Medium
11/18/2021The Goldman Sachs GroupInitiated CoverageBuyHigh
10/8/2021Morgan StanleyLower TargetEqual Weight$176.00 ➝ $174.00Low
10/5/2021CitigroupInitiated CoverageBuy$200.00Medium
9/22/2021Needham & Company LLCInitiated CoverageBuy$220.00High
8/16/2021HC WainwrightLower TargetBuy$220.00 ➝ $210.00Low
7/23/2021Royal Bank of CanadaBoost TargetOutperform$190.00 ➝ $216.00Low
7/22/2021SVB LeerinkReiterated RatingBuyLow
7/6/2021Jefferies Financial GroupInitiated CoverageBuy$220.00Low
6/22/2021BarclaysBoost TargetOverweight$235.00 ➝ $250.00Low
6/21/2021HC WainwrightBoost TargetBuy$212.00 ➝ $220.00Low
6/18/2021SVB LeerinkBoost TargetOutperform$210.00 ➝ $230.00Low
5/24/2021Piper SandlerReiterated RatingBuy$214.00Low
5/19/2021JPMorgan Chase & Co.Initiated CoverageOverweightLow
5/17/2021HC WainwrightBoost TargetBuy$207.00 ➝ $212.00Medium
5/9/2021SVB LeerinkReiterated RatingBuyLow
5/7/2021Jefferies Financial GroupReiterated RatingBuyLow
4/21/2021Cantor FitzgeraldBoost TargetOverweight$185.00 ➝ $198.00Medium
4/14/2021Stifel NicolausBoost TargetBuy$195.00 ➝ $202.00High
4/1/2021Morgan StanleyBoost TargetEqual Weight$162.00 ➝ $176.00Low
3/15/2021SVB LeerinkReiterated RatingOutperformMedium
3/1/2021UBS GroupBoost TargetBuy$174.00 ➝ $228.00Low
2/25/2021SVB LeerinkLower TargetOutperform$213.00 ➝ $210.00Medium
2/24/2021CowenBoost TargetOutperform$190.00 ➝ $200.00High
2/24/2021Jefferies Financial GroupBoost TargetBuy$209.00 ➝ $214.00High
2/24/2021Piper SandlerBoost TargetOverweight$175.00 ➝ $205.00High
2/5/2021HC WainwrightBoost TargetBuy$195.00 ➝ $207.00High
2/3/2021Piper SandlerUpgradeNeutral ➝ Overweight$150.00 ➝ $175.00High
1/29/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$177.00 ➝ $162.00High
12/15/2020UBS GroupInitiated CoverageBuy$174.00High
11/3/2020Wells Fargo & CompanyBoost TargetOverweight$171.00 ➝ $184.00High
11/3/2020Royal Bank of CanadaBoost TargetOutperform$170.00 ➝ $180.00High
11/3/2020BarclaysBoost TargetOverweight$225.00 ➝ $233.00High
11/3/2020SVB LeerinkBoost TargetOutperform$194.00 ➝ $202.00High
11/3/2020HC WainwrightBoost TargetBuy$185.00 ➝ $195.00High
10/26/2020BarclaysBoost TargetOverweight$205.00 ➝ $225.00Low
10/20/2020Truist FinancialBoost Target$157.00 ➝ $175.00Medium
10/9/2020Jefferies Financial GroupBoost TargetBuy$151.00 ➝ $188.00Low
10/9/2020SVB LeerinkBoost TargetOutperform$164.00 ➝ $182.00Low
10/9/2020HC WainwrightBoost TargetBuy$175.00 ➝ $185.00Low
9/14/2020Royal Bank of CanadaBoost Target$160.00 ➝ $170.00Low
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweight$175.00Medium
9/14/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$128.00Medium
8/13/2020Wells Fargo & CompanyBoost TargetOverweight$150.00 ➝ $171.00Low
8/6/2020BarclaysReiterated RatingBuyHigh
8/6/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$177.00High
7/30/2020OppenheimerInitiated CoverageOutperformHigh
7/28/2020Wolfe ResearchUpgradePeer Perform ➝ OutperformLow
7/23/2020HC WainwrightUpgradeNeutral ➝ Buy$145.00 ➝ $166.00Medium
6/23/2020BarclaysBoost TargetOverweight$183.00 ➝ $195.00Low
6/18/2020Bank of AmericaBoost TargetBuy$165.00 ➝ $167.00Low
6/1/2020SVB LeerinkBoost TargetOutperform$160.00 ➝ $169.00Low
5/6/2020SunTrust BanksLower TargetBuy$155.00 ➝ $153.00Medium
5/6/2020OppenheimerReiterated RatingBuy$132.00Medium
5/6/2020SVB LeerinkLower TargetOutperform$169.00 ➝ $160.00Medium
5/6/2020BMO Capital MarketsLower TargetPositive ➝ Outperform$205.00 ➝ $193.00High
5/6/2020Piper SandlerLower TargetNeutral$127.00 ➝ $113.00High
4/30/2020Wells Fargo & CompanyLower TargetOverweight$189.00 ➝ $162.00Low
4/30/2020OppenheimerLower TargetOutperform$154.00 ➝ $141.00Low
4/6/2020Jefferies Financial GroupInitiated CoverageBuy$149.00High
4/2/2020Morgan StanleyLower TargetEqual Weight$147.00 ➝ $109.00Medium
3/30/2020Royal Bank of CanadaLower Target$164.00 ➝ $174.00Medium
3/23/2020Bank of AmericaLower TargetBuy$178.00 ➝ $163.00High
3/12/2020Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$175.00 ➝ $166.00High
2/27/2020SunTrust BanksLower TargetBuy$171.00 ➝ $166.00High
2/26/2020OppenheimerLower Target$183.00 ➝ $154.00High
2/26/2020Piper SandlerLower Target$142.00 ➝ $129.00High
2/26/2020BMO Capital MarketsLower TargetOutperform$208.00 ➝ $205.00High
2/26/2020Royal Bank of CanadaReiterated RatingOutperform$164.00High
2/26/2020CowenLower TargetOutperform$200.00 ➝ $165.00High
2/26/2020JPMorgan Chase & Co.Boost TargetOverweight$173.00 ➝ $183.00High
1/31/2020SunTrust BanksReiterated RatingBuy$166.00 ➝ $171.00Low
1/22/2020Wells Fargo & CompanyBoost TargetOverweight$186.00 ➝ $189.00Low
1/8/2020The Goldman Sachs GroupInitiated CoverageNeutral$153.00Medium
12/3/2019Wells Fargo & CompanyBoost TargetOutperform$168.00 ➝ $186.00High
12/2/2019BarclaysBoost TargetOverweight$182.00 ➝ $200.00Low
11/11/2019HC WainwrightReiterated RatingHold$147.00Medium
11/11/2019Evercore ISIReiterated RatingBuyMedium
11/7/2019BarclaysReiterated RatingBuy$182.00Medium
10/14/2019Sanford C. BernsteinReiterated RatingMarket Perform$150.00Low
9/26/2019OppenheimerSet TargetBuy$176.00Low
8/21/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$205.00 ➝ $142.00High
8/14/2019Wells Fargo & CompanyReiterated RatingBuyLow
8/12/2019Evercore ISIReiterated RatingBuyMedium
8/8/2019HC WainwrightReiterated RatingHold$147.00Low
8/7/2019BarclaysBoost TargetOverweight$164.00 ➝ $180.00High
7/8/2019OppenheimerSet TargetBuy$176.00Low
7/3/2019Royal Bank of CanadaSet TargetBuy$184.00Low
7/3/2019BarclaysSet TargetBuy$164.00Low
7/3/2019BMO Capital MarketsSet TargetBuy$208.00Low
7/3/2019MizuhoSet TargetHold$148.00Low
6/17/2019Wells Fargo & CompanyReiterated RatingBuyLow
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$164.00Low
5/28/2019Piper Jaffray CompaniesSet TargetBuy$202.00Low
5/10/2019HC WainwrightReiterated RatingHold$153.00Low
5/8/2019MizuhoBoost TargetNeutral$146.00 ➝ $148.00High
5/8/2019BMO Capital MarketsBoost TargetOutperform$206.00 ➝ $208.00High
3/27/2019MizuhoReiterated RatingNeutral ➝ Hold$137.00 ➝ $147.00Medium
3/26/2019Cantor FitzgeraldReiterated RatingBuy$185.00Medium
3/19/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$163.00Medium
3/19/2019Wells Fargo & CompanySet TargetBuy$162.00Low
3/18/2019Royal Bank of CanadaSet TargetBuy$184.00Low
3/8/2019Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$168.00 ➝ $135.00Medium
2/27/2019BMO Capital MarketsBoost TargetOutperform ➝ Outperform$199.00 ➝ $206.00Medium
2/26/2019Cantor FitzgeraldSet TargetBuy$185.00Low
2/13/2019CowenReiterated RatingBuy$200.00Medium
2/12/2019Cantor FitzgeraldReiterated RatingBuy$185.00Medium
1/4/2019Cantor FitzgeraldSet TargetBuy$201.00Low
12/23/2018Wells Fargo & CompanyReiterated RatingBuyMedium
12/23/2018OppenheimerSet TargetBuy$180.00Medium
12/14/2018Wolfe ResearchInitiated CoveragePeer Perform ➝ Peer PerformLow
12/11/2018OppenheimerInitiated CoverageBuy$180.00 ➝ $180.00Low
11/28/2018Morgan StanleySet TargetHold$168.00Low
11/20/2018MizuhoLower TargetNeutral$157.00Low
11/14/2018HC WainwrightReiterated RatingHold$161.00Medium
11/8/2018B. RileyLower TargetBuy ➝ Buy$219.00 ➝ $190.00Medium
11/7/2018CowenSet TargetBuy$200.00High
11/7/2018Wells Fargo & CompanyReiterated RatingBuyHigh
11/7/2018Royal Bank of CanadaSet TargetBuy$184.00High
11/7/2018Piper Jaffray CompaniesSet TargetBuy$208.00High
11/6/2018Cantor FitzgeraldReiterated RatingBuy$201.00High
10/19/2018Piper Jaffray CompaniesSet TargetBuy$213.00Low
10/15/2018MizuhoReiterated RatingNeutral$173.00High
8/17/2018SVB LeerinkBoost TargetOutperform$200.00 ➝ $210.00Low
8/15/2018Wells Fargo & CompanyReiterated RatingBuy$182.00 ➝ $195.00Medium
8/9/2018HC WainwrightReiterated RatingHold$167.00Low
8/8/2018BMO Capital MarketsBoost TargetOutperform ➝ Outperform$201.00 ➝ $206.00Medium
8/8/2018Stifel NicolausBoost TargetBuy ➝ Buy$180.00 ➝ $205.00High
8/8/2018Piper Jaffray CompaniesReiterated RatingBuy$213.00High
8/7/2018Cantor FitzgeraldSet TargetBuy$203.00High
7/13/2018Evercore ISIReiterated RatingBuyLow
7/11/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$183.00Low
7/10/2018CitigroupBoost TargetBuy ➝ Buy$162.00 ➝ $205.00Low
7/8/2018Wells Fargo & CompanyReiterated RatingBuyLow
7/2/2018Wells Fargo & CompanyReiterated RatingBuyLow
6/26/2018B. RileyBoost TargetBuy ➝ Buy$211.00 ➝ $219.00Low
6/1/2018Royal Bank of CanadaSet TargetBuy$194.00Low
5/15/2018Wells Fargo & CompanySet TargetOutperform$176.00 ➝ $182.00Low
5/10/2018B. RileyBoost TargetBuy ➝ Buy$206.00 ➝ $211.00Medium
5/9/2018MizuhoReiterated RatingHold$150.00High
5/9/2018HC WainwrightSet TargetHold$160.00Low
5/9/2018BMO Capital MarketsBoost TargetOutperform ➝ Outperform$199.00 ➝ $201.00Medium
4/30/2018Cantor FitzgeraldReiterated RatingBuy$202.00High
3/23/2018HC WainwrightReiterated RatingNeutral$150.00 ➝ $160.00Medium
3/19/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$128.58 ➝ $163.75High
3/1/2018Piper Jaffray CompaniesReiterated RatingBuy$201.00Low
2/28/2018BMO Capital MarketsBoost TargetOutperform ➝ Outperform$196.00 ➝ $199.00High
2/20/2018Bank of AmericaBoost TargetBuy ➝ Buy$164.00 ➝ $170.00Low
1/16/2018B. RileyReiterated RatingBuy$206.00Low
1/16/2018Deutsche Bank AktiengesellschaftSet TargetBuy$170.00Medium
1/2/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$180.00Low
12/25/2017Wells Fargo & CompanyReiterated RatingBuyLow
12/20/2017B. RileyReiterated RatingBuy$206.00Low
12/10/2017Cantor FitzgeraldReiterated RatingBuy$200.00Low
12/5/2017B. RileyReiterated RatingBuy$206.00Low
12/5/2017MizuhoBoost TargetNeutral ➝ Neutral$144.00 ➝ $150.00Low
12/3/2017Cantor FitzgeraldReiterated RatingBuy$200.00Low
11/10/2017HC WainwrightReiterated RatingNeutral ➝ Neutral$144.00 ➝ $150.00N/A
11/8/2017UBS GroupLower TargetBuy$172.00 ➝ $168.00N/A
11/8/2017Wells Fargo & CompanyReiterated RatingOutperform$177.00 ➝ $172.00N/A
11/8/2017Royal Bank of CanadaLower TargetOutperform$210.00 ➝ $195.00N/A
11/8/2017Royal Bank of CanadaReiterated RatingOutperform$210.00 ➝ $195.00N/A
10/26/2017Stifel NicolausReiterated RatingBuy$190.00N/A
10/23/2017CowenSet TargetBuy$190.00N/A
10/21/2017Piper Jaffray CompaniesSet TargetBuy$177.00N/A
10/19/2017FBR & Co.Initiated CoverageBuy ➝ Buy$206.00N/A
10/5/2017Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$155.00N/A
(Data available from 10/2/2017 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/6/2022
  • 1 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/5/2022
  • 6 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
5/5/2022
  • 4 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/4/2022
  • 6 very positive mentions
  • 5 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
7/4/2022
  • 8 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/3/2022
  • 8 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
9/2/2022
  • 4 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
10/2/2022

Current Sentiment

  • 4 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Jazz Pharmaceuticals logo
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $133.29
Low: $132.45
High: $136.60

50 Day Range

MA: $150.54
Low: $126.59
High: $161.18

52 Week Range

Now: $133.29
Low: $117.64
High: $169.98

Volume

843,420 shs

Average Volume

617,932 shs

Market Capitalization

$8.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Jazz Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Jazz Pharmaceuticals in the last twelve months: BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Cowen Inc, Cowen Inc., HC Wainwright, Morgan Stanley, Needham & Company LLC, Piper Sandler, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for JAZZ.

What is the current price target for Jazz Pharmaceuticals?

13 Wall Street analysts have set twelve-month price targets for Jazz Pharmaceuticals in the last year. Their average twelve-month price target is $201.69, suggesting a possible upside of 51.3%. Cowen Inc. has the highest price target set, predicting JAZZ will reach $225.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $170.00 for Jazz Pharmaceuticals in the next year.
View the latest price targets for JAZZ.

What is the current consensus analyst rating for Jazz Pharmaceuticals?

Jazz Pharmaceuticals currently has 2 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe JAZZ will outperform the market and that investors should add to their positions of Jazz Pharmaceuticals.
View the latest ratings for JAZZ.

What other companies compete with Jazz Pharmaceuticals?

How do I contact Jazz Pharmaceuticals' investor relations team?

Jazz Pharmaceuticals' physical mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company's listed phone number is (531) 634-7800 and its investor relations email address is [email protected] The official website for Jazz Pharmaceuticals is www.jazzpharma.com. Learn More about contacing Jazz Pharmaceuticals investor relations.